Explore ViiV Healthcare
Research and development of new HIV medicines
At ViiV Healthcare we are committed to playing our part in addressing access to medicines challenges by taking an innovative, responsible, and sustainable approach.
13.6 million people who are eligible for antiretroviral therapy currently have access to HIV medicines but current estimates based on the recently updated WHO guidelines are that the number of people who need treatment is 28.6 million.
We recognise that we are a key stakeholder in the global effort to improve access, and have committed as a company to continue to work with the HIV community to help deliver on WHO/UNAIDS goals to reach all those who need treatment.
To help meet the pressing need for a global effort to address the barriers to scaling up and treating those in need, we have already launched industry-leading access initiatives, and we are constantly evaluating these programmes to look for ways to improve them even further.
Our access to medicines approach covers all Middle Income Countries, all Low Income Countries, all Least Developed Countries and Sub-Saharan Africa, i.e.138 countries in total. We do this through a variety of approaches, based on the differing needs of people living with HIV in different parts of the world:
Low Income, Least Developed Countries and Sub Saharan Africa – Where 25 million People With HIV/AIDS live (=75% of the total)
In these countries which have the lowest incomes, and/or are hardest hit by the global epidemic, we recognise that there is a global imperative to take action, and, in response, we have a broad and deep approach to improving access to our medications.
We do this by:
- Royalty Free Voluntary Licenses: Our royalty free voluntary licensing policy covers all of our current medicines (including those in our pipeline, once licensed) for public sector and donor agency programmes in all Low Income Countries, all Least Developed Countries and all of Sub-Saharan Africa. ViiV Healthcare has given 16 voluntary licences for our ARVs to generic manufacturers. These companies are based in a broad range of different locations. We do not charge royalties in respect of these countries.
Middle Income Countries, i.e. Emerging and Newly Industrialised Economies
- Flexible Pricing: In Middle Income Countries, where incomes are higher and infrastructure is more developed, we have a flexible pricing policy which factors in the gross domestic product (GDP) and the impact of the epidemic in each country to improve affordability. In these countries, including some of the fastest growing economies in the world, there is a need for government commitment and accountability to scaling up the national response to the HIV epidemic.
- Local Partnerships: We approach these on a case-by-case basis, taking into account the local needs and situation.
Click to view ViiV Healthcare Policies on:
Stigma and discrimination have a significant negative impact on access to treatment and care and the overall HIV response globally. Click here to view ViiV Healthcare Policy on Stigma and discrimination.